Tissue-specific Wnt signal enhancing molecules and uses thereof
AssigneeSurrozen Operating, Inc.
InventorsZhengjian Zhang, Jennifer Jean Brady, Aaron Ken Sato, Wen-Chen Yeh, Yang Li, Teppei Yamaguchi
Life of this patent
Estimating the term…
Abstract
The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.
Claims14
A tissue-specific Wnt (“Wingless-related integration site” or “Wingless and Int-I” or “Wingless-Int”) signal enhancing molecule, or a pharmaceutically acceptable salt thereof, comprising:
- (a) a first domain comprising two R-spondin 2 polypeptides, or fragments thereof comprising the furin I domain of the R-spondin 2 polypeptide, wherein the R-spondin 2 polypeptides comprise amino acid substitutions at amino acids corresponding to F105 and F109 of human R-spondin 2 of SEQ ID NO:2, and wherein the first domain specifically binds one or more-transmembrane E3 ubiquitin ligases, wherein the one or more transmembrane E3 ubiquitin ligases are Zinc and Ring Finger 3 (ZNRF3) and Ring Finger Protein 43 (RNF43);
- and
- (b) a second domain comprising an Immunoglobulin G (IgG) antibody;
- wherein the second domain specifically binds a tissue-specific cell surface molecule, wherein the tissue-specific cell surface molecule is an asialoglycoprotein receptor I (ASGRI), and wherein the IgG antibody comprises two heavy chain polypeptides and two light chain polypeptides, wherein each light chain polypeptide comprises SEQ ID NO:
- 72, and each heavy chain polypeptide comprises SEQ ID NO:
- 86,
- wherein the R-spondin 2 polypeptides are fused to the heavy chain polypeptides of the IgG antibody.
A tissue-specific Wnt (“Wingless-related integration site” or “Wingless and Int-I” or “Wingless-Int”) signal enhancing molecule, or pharmaceutically acceptable salt thereof, wherein the molecule comprises:
- a) two polypeptides of SEQ ID NO:72 and two polypeptides of SEQ ID NO:74;
- or
- b) two polypeptides of SEQ ID NO:72 and two polypeptides of SEQ ID NO:86.
Dependencies are inferred from the claim text.